Category Archives: Malaria

Nobel prize winners point the way in battle against diseases of poverty

The Guardian; October 30, 2015. What does it take to bring the fruits of scientific innovation to vulnerable patients in the world’s poorest communities? The discoveries recognised by the 2015 Nobel prize for medicine are perfect examples of the journey from test … Continue reading

Posted in Innovation, Malaria, Neglected Diseases | Leave a comment

Took 400 injections, Had a Lung Removed: A TB Survivor’s Account

Source: NDTV 31 Mar 2015 (Deepti Chavan is an MDR-TB survivor and is now a spokesperson for the rights of TB patients in India.) I was 16 and appearing for my board exams when I first started feeling sick. The … Continue reading

Posted in Malaria | Leave a comment

Is the Global Fund Heading Backwards on Access to Medicines?

Source: PLOS Suerie Moon from the Harvard School of Public Health warns against falling back on stale solutions for ensuring access to essential medicines.  For nearly a decade, a bright spot on World AIDS Day has been steady growth in the number … Continue reading

Posted in Generics, HIV/Aids, IP Rights, IPR Enforcement, Malaria, Patents, Pricing, Right to Health, Tuberculosis (TB), WHO | Tagged , , , , | Leave a comment

Oral Testimony at US Congressional Hearing: “A Tangle of Trade Barriers: How India’s Industrial Policy is Hurting U.S. Companies.”

Source:  MSF Access Campaign Speaker:  Rohit Malpani – Director, Policy & Analysis, MSF Access Campaign Washington, DC – June 27, 2013 Good morning. My name is Rohit Malpani and I am the Director of Policy and Analysis at Doctors Without … Continue reading

Posted in Compulsory Licensing, Evergreening, Generics, IP Rights, Malaria, Novartis Case, Right to Health, TRIPS, TRIPS flexibilities, WTO | Tagged , , , , , , , | Leave a comment

Analysis: Antibiotics crisis prompts rethink on risks, rewards

Source: Reuters Analysis: Antibiotics crisis prompts rethink on risks, rewards. Today, as the world confronts another crisis, this time one of antibiotic resistance, the industry is doing the opposite. It is cutting research in a field that offers little scope … Continue reading

Posted in Malaria | Tagged , , , | Leave a comment

Novartis seeks predictable interpretation of law in high octane Indian Glivec case

22 February 2012 14:43 The crucial Indian patent case concerning Novartis’ anticancer Glivec (imatinib mesylate) and its rejection due to Section 3(d), a controversial provision in India’s patent law, comes up for hearing next week, amid hope and concern for … Continue reading

Posted in HIV/Aids, Indian Patent Law, intellectual property training, IP Rights, Malaria, Novartis Case | 2 Comments